DOCSLIB.ORG

Validated RP-HPLC Method for Determination of Bromhexine Hcl, Chlorpheniramine Maleate, Dextromethorphan Hbr and Guaiphenesin in Pharmaceutical Dosage Forms

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Validated RP-HPLC Method for Determination of Bromhexine Hcl, Chlorpheniramine Maleate, Dextromethorphan Hbr and Guaiphenesin in Pharmaceutical Dosage Forms Accepted Manuscript Title: Validated RP-HPLC Method for determination of Bromhexine HCl, Chlorpheniramine Maleate, Dextromethorphan HBr and Guaiphenesin in Pharmaceutical Dosage Forms Author: Vishal Jain Mukesh C. Sharma PII: S1658-3655(15)00063-1 DOI: http://dx.doi.org/doi:10.1016/j.jtusci.2015.02.019 Reference: JTUSCI 172 To appear in: Received date: 15-11-2014 Revised date: 7-2-2015 Accepted date: 15-2-2015 Please cite this article as: Vishal, Validated RP-HPLC Method for determination of Bromhexine HCl, Chlorpheniramine Maleate, Dextromethorphan HBr and Guaiphenesin in Pharmaceutical Dosage Forms, Journal of Taibah University for Science (2015), http://dx.doi.org/10.1016/j.jtusci.2015.02.019 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Validated RP-HPLC Method for determination of Bromhexine HCl, Chlorpheniramine Maleate, Dextromethorphan HBr and Guaiphenesin in Pharmaceutical Dosage Forms Vishal Jain and Mukesh C. Sharma* * School of Pharmacy, Devi Ahilya Vishwavidyalaya, Takshashila Campus, Indore (M.P.) 452001, India * Corresponding Author E-mail: [email protected], [email protected] Accepted Manuscript Page 1 of 17 Abstract A simple, precise and accurate reverse phase high performance liquid chromatographic method has been developed for simultaneous estimation of Bromhexine hydrochloride, Chlorpheniramine maleate, Dextromethorphan hydrobromide and Guaiphenesin in their tablet dosage form. The chromatographic conditions were standardized using Chromatopak C18 (25cm×4.6mm i.d.×5µm) with UV detection at 265 nm and mobile phase consisting of methanol: acetonitrile: 0.025 M phosphate buffer (50: 25: 25 v/v/v). The retention times of Bromhexine hydrochloride, Chlorpheniramine maleate, Dextromethorphan hydrobromide and Guaiphenesin have been found to be 16.254 min, 12.219 min, 6.156 min and 9.432 min respectively. Calibration curves were linear with correlation coefficient 0.9987, 0.9988, 0.9981 and 0.9981 over a concentration range of 4.0 µg/ml-24.0 µg/ml for Bromhexine hydrochloride, 5.0-30.0 µg/ml for Chlorpheniramine maleate, 10.0-60.0 µg/ml for both Dextromethorphan hydrobromide and Guaiphenesin respectively. The proposed method has been validated as per guideline of ICH and successfully applied to the estimation of four drugs in combined formulation to the determination of the examined drugs with good accuracy and precision. Keywords: RP-HPLC, Bromhexine hydrochloride, Chlorpheniramine maleate, Dextromethorphan hydrobromide, Guaiphenesin, ICH guideline Accepted Manuscript Page 2 of 17 1. Introduction Combinations of decongestant, and antihistaminic, preparations are widely used for cough and cold treatment. Bromhexine HCl (Fig:1), chemically named 2-amino-3, 5-dibromo-N- cyclohexyl-N-methyl benzenemethanamine hydrochloride, is a mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus [1, 2]. Its mechanism is by increasing the production of serous mucus in the respiratory tract and makes the phlegm thinner and less viscous. Bromhexine HCl (BROM) is a mucous modifying drug helps to improve the flow properties of bronchial mucous and eases expectoration. A literature survey reveals some HPLC methods reported for the simultaneous determination of along with some other active ingredients which exist as various combinations in cough-cold mixture [3], liquid chromatography [4], liquid gas chromatography [5], Gas Chromatography with mass detection [6], combined formulations using HPLC [7-9] and UV spectrophotometric [10-13]. Chlorpheniramine maleate (CHL), 3-(p-chlorophenyl)-3-(2-pyridyl)-N,N-dimethyl propylamine (Fig:1), is a powerful first-generation alkyl amine antihistamine, H1-receptor antagonist, widely used for symptomatic relief of common cold and allergic rhinitis, with weak sedative properties [14]. These symptoms include rash, watery eyes, itchy eyes, throat, cough, and sneezing. It is also effective against nausea and motion sickness, with its primary mechanism of action being its ability to reduce acetylcholine levels in the brain. Literature survey shows that several HPLC methods have been reported for chlorpheniramine maleate single and in combinations in pharmaceuticals liquid chromatographic [15-17], HPTLC [18], spectrophotometry [19] and micellar electrokinetic chromatography [20]. Dextromethorphan hydrobromide (DEX), [(+)-3- Methoxy-17-methyl-9α, 13α, 14α morphinan hydrobromide monohydrate] is a cough suppressant, used for the relief of non-productive cough; it has a central action on the cough centre in the medulla [21]. Dextromethorphan hydrobromide (DEX) is an antitussive drug and used for pain relief and psychological applications [22]. The chemical structures of DEX are shown in Fig: 1.Accepted The combination of these drugs Manuscript is used as antitussive and mucolytic in bronchitis and chronic pulmonary conditions. Several analytical techniques have been reported in the literature, most commonly liquid chromatography [23-24], first and second-derivative technique UV spectrophotometric [25-27] capillary electrophoresis [28] Gas Chromatography [29]. Guaiphenesin (GUA; Fig: 1) is (2RS)-3-(2-methoxyphenoxy) propane-1, 2-diol [30], it is reported to increase the volume and reduce the viscosity of tenacious sputum and is used as an expectorant for productive cough. It is the glyceryl ether of guaiacol (a constituent of guaiac resin from the wood of Guajacum officinale Linne), it act as expectorant by increasing the Page 3 of 17 volume and reducing the viscosity of secretions in the trachea and bronchi. It is the component of numerous cough cold preparations available worldwide. Also it has been given to patients with altered nasal mucociliary clearance associated with HIV infection [31]. The literature survey revealed that some techniques have been published for the determination of Guaifenesin either in their combined form or in combinations with other drugs by capillary gas chromatography [32], HPLC [33], LC-MS [34], LC-MS/MS [35-36]. There is no method reported for the simultaneous estimation of Bromhexine hydrochloride (BROM), Chlorpheniramine maleate (CHL), Dextromethorphan hydrobromide (DEX) and Guaiphenesin (GUA) in combined dosage form. Therefore, communicate here rapid and cost- effective quality-control tool and reliable method for simultaneous assay of these four drugs in mixture seemed to be necessary. The method should have sufficient accuracy and precision and permit a simple and time-saving assay of BROM - CHL - DEX and GUA in mixtures. 2. MATERIALS AND METHODS 2.1 Apparatus To develop a suitable LC method for the analysis of BROM, CHL, DEX and GUA in their combined dosage form, different mobile phases were tried. The Chromatographic system consists of pump (Shimadzu LC 10AT VP ) with universal loop injector (Rheodyne 7725i) of injection capacity 20 µL. Detector consists of photodiode array detector (PDA) SPD-10 AVP UV-Visible detector and column used was Chromatopak C18 (25cm×4.6mm i.d.×5µm). The equipment was controlled by a PC work station equipped with software CLASS M 10-VP software (Shimadzu, Kyoto, Japan). UV/Visible double beam spectrophotometer (Shimadzu Model 1700) was employed with spectral bandwidth of 1nm and wavelength accuracy of 0.3 nm (with automatic wavelength correction with a pair of 1cm matched quartz cells). 2.2. Reagents and Materials Pure drugs sampleAccepted BROM, CHL, DEX and GUA were Manuscript generously obtained as a gift sample from TABLIKE and SCHON Pharmaceutical, Indore, India. The tablet doses form, MARICOF, (Label claim: 8.0 mg BROM, 2.0 mg CHL, 10.0 mg DEX and 100.0 mg GUA) was procured from the local market (Manufactured by G.S. Pharmaceuticals Pvt. Ltd., Roorkee, India). HPLC grade methanol and acetonitrile were obtained from Merck (Mumbai, India). 2.3 Chromatography conditions Page 4 of 17 The solubility of the four drugs indicated that reversed phase chromatographic method would be best option for simultaneous estimation of BROM, CHL, DEX, and GUA. The mobile phase consists of organic phase methanol, acetonitrile and 0.025M phosphate buffer in the ratio of 50:25:25 (v/v/v adjusted to pH 5.5 using orthophosphoric acid). Mobile phase and working solutions were filtered through 0.2 µm nylon and degassed using sonicator before use. To determine the appropriate wavelength for simultaneous determination of BROM, CHL, DEX, and GUA solutions of these compounds were scanned by UV-visible spectrophotometer in a range 200- 400nm. From the overlain UV spectra suitable wavelength choices considered for monitoring these drugs was 265 nm. 2.4 Preparation of standard stock solutions Standard stock solution of BROM, CHL, DEX and GUA were prepared separately by dissolving accurately weighed 10.0 mg of each BROM, CHL, DEX and GUA (reference standard) transfer it to 20.0 ml of HPLC grade methanol in 100 ml volumetric flask. Sonicated in bath sonicator for 10 minutes to ensure complete solubilization. After sonication, the volume was made up to the mark 100 ml. with same solvent HPLC grade methanol, to result in a final concentration of 0.1 mg/ml (100µg/ml) of each reference standard. A combined
Load more

Recommended publications
  • 2020 Equine Prohibited Substances List CONTROLLED MEDICATION
    2020 Equine Prohibited Substances List CONTROLLED MEDICATION . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s). Prohibited Substances that are identified as Specified Substances in the List below should not in any way be considered less important or less dangerous than other Prohibited Substances. Rather, they are simply substances which are more likely to have been ingested by Horses for a purpose other than the enhancement of sport performance, for example, through a contaminated food substance. SUBSTANCE ACTIVITY 17-Alpha-Hydroxy Progesterone FEMALES Hormone Acepromazine Sedative Acetazolamide Carbonic Anhydrase Inhibitor Acetominophen (Paracetamol) Analgesic Adrenaline Stimulant Adrenocorticotropic hormone (ACTH) Hormone Aformoterol Bronchodilator Albuterol (Salbutamol) Bronchodilator Alpha-Casozepine Sedative Altrenogest (in males and geldings) Oestrus suppression Amantadine Dopaminergic Ambroxol Mucolytic Amcinonide Corticosteroid Aminocaproic acid Haemostatic (anti-fibrinolytic) Aminophylline Bronchodilator Aminorex Parasympathomimetic Amiodarone Anti-arrhythmic Antazoline Antihistamine Atipamezole Alpha adrenergic antagonist Atropine (Specified Substance) Anticholinergic Azatadine Antihistamine Beclomethasone Corticosteroid Benzocaine (Ethyl Aminobenzoate) Local anaesthetic Benzquinamide Antihistamine Benzydamine Non-steroidal anti-inflammatory drug Betamethasone Corticosteroid Bethanechol Parasympathetic agonist Brinzolamide Diuretic Bromhexine Mucolytic Bromodiphenhydramine
    [Show full text]
  • National OTC Medicines List
    National OTC Medicines List ‐ DraŌ 01 DRAFT National OTC Medicines List Draft 01 Ministry of Public Health of Lebanon This list was prepared under the guidance of His Excellency Minister Waêl Abou Faour andDRAFT the supervision of the Director General Dr. Walid Ammar. Editors Rita KARAM, Pharm D. PhD. Myriam WATFA, Pharm D Ghassan HAMADEH, MD.CPE FOREWORD According to the French National Agency for Medicines and Health Products Safety (ANSM), Over-the-counter (OTC) drugs are medicines that are accessible to patients in pharmacies, based on criteria set to safeguard patients’ safety. Due to their therapeutic class, these medicines could be dispensed without physician’s intervention for diagnostic, treatment initiation or maintenance purposes. Moreover, their dosage, treatment period and Package Insert Leaflet should be suitable for OTC classification. The packaging size should be in accordance with the dosage and treatment period. According to ArticleDRAFT 43 of the Law No.367 issued in 1994 related to the pharmacy practice, and the amendment of Articles 46 and 47 by Law No.91 issued in 2010, pharmacists do not have the right to dispense any medicine that is not requested by a unified prescription, unless the medicine is mentioned in a list which is established by pharmacists and physicians’ syndicates. In this regard, the Ministry of Public Health (MoPH) developed the National OTC Medicines List, and presentedit in a scientific, objective, reliable, and accessible listing. The OTC List was developed by a team of pharmacists and physicians from the Ministry of Public Health (MoPH). In order to ensure a safe and effective self- medicationat the pharmacy level, several pharmaceutical categories (e.g.
    [Show full text]
  • Mucoactive Agents for Airway Mucus Hypersecretory Diseases
    Mucoactive Agents for Airway Mucus Hypersecretory Diseases Duncan F Rogers PhD FIBiol Introduction Sputum Profile of Airway Inflammation and Mucus Hypersecretory Phenotype in Asthma, COPD, and CF Which Aspect of Airway Mucus Hypersecretion to Target? Theoretical Requirements for Effective Therapy of Airway Mucus Hypersecretion Current Recommendations for Clinical Use of Mucolytic Drugs Mucoactive Drugs N-Acetylcysteine: How Does it Work? Does it Work? Dornase Alfa Hypertonic Saline Surfactant Analysis Summary Airway mucus hypersecretion is a feature of a number of severe respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF). However, each disease has a different airway inflammatory response, with consequent, and presumably linked, mucus hypersecretory phenotype. Thus, it is possible that optimal treatment of the mucus hyper- secretory element of each disease should be disease-specific. Nevertheless, mucoactive drugs are a longstanding and popular therapeutic option, and numerous compounds (eg, N-acetylcysteine, erdosteine, and ambroxol) are available for clinical use worldwide. However, rational recommen- dation of these drugs in guidelines for management of asthma, COPD, or CF has been hampered by lack of information from well-designed clinical trials. In addition, the mechanism of action of most of these drugs is unknown. Consequently, although it is possible to categorize them according to putative mechanisms of action, as expectorants (aid and/or induce cough), mucolytics (thin
    [Show full text]
  • Bromhexine Hydrochloride
    Bromhexine Hydrochloride sc-204656 Material Safety Data Sheet Hazard Alert Code EXTREME HIGH MODERATE LOW Key: Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION PRODUCT NAME Bromhexine Hydrochloride STATEMENT OF HAZARDOUS NATURE CONSIDERED A HAZARDOUS SUBSTANCE ACCORDING TO OSHA 29 CFR 1910.1200. NFPA FLAMMABILITY1 HEALTH3 HAZARD INSTABILITY0 SUPPLIER Company: Santa Cruz Biotechnology, Inc. Address: 2145 Delaware Ave Santa Cruz, CA 95060 Telephone: 800.457.3801 or 831.457.3800 Emergency Tel: CHEMWATCH: From within the US and Canada: 877-715-9305 Emergency Tel: From outside the US and Canada: +800 2436 2255 (1-800-CHEMCALL) or call +613 9573 3112 PRODUCT USE Expectorant. Reported to change the structure of bronchial secretions and to increase the volume and reduce the viscosity of sputum. Administered in bronchitis and other respiratory conditions. Normally given by mouth. Synthetic derivative of vasicine, the active principal of Adhatoda vasica. SYNONYMS C14-H20-Br2-N2.HCl, "2-amino-N-cyclohexyl-3, 5-dibromo-N-methylbenzylamine hydrochloride", "2-amino-N-cyclohexyl-3, 5-dibromo-N-methylbenzylamine hydrochloride", "benzenemethanamine, 2-amino-3, 5-dibromo-N-cyclohexyl-N-methyl-, ", "benzenemethanamine, 2-amino-3, 5-dibromo-N-cyclohexyl-N-methyl-, ", monohydrochloride, "benzylamine, 2-amino-N- cyclohexyl-3, 5-dibromo-N-methyl-, hydrochloride", "benzylamine, 2-amino-N-cyclohexyl-3, 5-dibromo-N-methyl-, hydrochloride", "bromhexin hydrochloride", "N-cyclohexyl-N-methyl-(2-amino-3, 5-dibromobenzyl) ammonium chloride", "N- cyclohexyl-N-methyl-(2-amino-3, 5-dibromobenzyl) ammonium chloride", Aletor, Bisolvomycin, Bisolvon, "Bisolvon Hydrochloride", Bromessina, Bromcilate, Bronkocin, "Dakroy Biciron", Ophtosol, "quaternary ammonium expectorant" Section 2 - HAZARDS IDENTIFICATION CANADIAN WHMIS SYMBOLS EMERGENCY OVERVIEW RISK Harmful if swallowed.
    [Show full text]
  • List Over Prohibited Substances and Withdrawal Times, Valid from January 1St, 2016 A. LIST of PROHIBITED SUBSTANCES
    Reviewed 01.06.16 List over prohibited substances and withdrawal times, valid from January 1st, 2016 This list has been developed in collaboration with the other Nordic countries through NEMAC (Nordic Equine Medication and Anti-doping Committee) and is reviewed yearly by the board of DNT (The Norwegian Trotting Association) (in accordance with DNT’s Doping Regulations 2016 § 3, 1st subsection). The List of prohibited substances and withdrawal times consists of the A-list, listing substances and treatment methods that are absolutely prohibited for horses, and the B-list, listing substances that are prohibited in competition; the withdrawal times for these substances as well as treatment methods with withdrawal times. The list may be reviewed several times per year. This list is valid starting from January 1st, 2016 and is enforced until a new list takes effect. A valid list of withdrawal times can be found at any time on DNT’s official website, www.travsport.no. Withdrawal times given on STC’s official website, www.travsport.se, are also valid in Norway. Health certificate and keeping of medical records The trainer is responsible for ensuring that any treatment that requires a withdrawal time is listed in the horse’s health certificate. The start and end dates of the treatment, the name of the treatment/medication/active substance, amount given, method of administration, withdrawal time as well as the name of the veterinarian or other person responsible for the treatment must all be listed in the health certificate in accordance with DNT’s Doping Regulations 2016 § 4. Passport and health certificate should be brought with the horse at all times.
    [Show full text]
  • Bromhexine Hydrochloride: Potential Approach to Prevent Or Treat Early Stage COVID-19
    Bromhexine Hydrochloride: Potential Approach to Prevent or Treat Early Stage COVID-19 D. Stepanova, P. Lierza aDepartment of Anesthesiology, Intensive Care, Pain Management and Palliative Care, Marienkrankenhaus, Soest, Germany Address Correspondence to Dmitry Stepanov, [email protected], Tel. 0049-2921-3917673 Abstract The most critical step during viral infection is when viruses enter the cell. A novel coronavirus SARS-CoV-2 penetrates into alveolar cells through the transmembrane serine protease TMPRSS2. Extensive studies show that a clinically approved drug from Japan and South Korea, camostat mesylate inactivates TMPRSS2 in order to prevent the infection. However, these basic studies have not been translated to “bedside”, and their effectiveness has not been clinically confirmed yet. Here, we describe another potential antiviral substance, commonly used in the clinical practice as a mucolytics – bromhexine hydrochloride. Causing only few mild side effects, it may serve as either a new therapeutic strategy during early stages of the disease or a preventive agent blocking SARS-CoV-2 entry into alveolar cells through TMPRSS2. Therefore, in this review, we discuss these possible approaches based on the current data. Keywords SARS-CoV-2; COVID-19; TMPRSS2; bromhexine; prophylaxis; therapy Introduction An emerging international outbreak of the novel coronavirus SARS-CoV-2 has already become a problem for physicians and scientists globally. Although the majority of patients withstand the novel 2019 coronavirus disease (COVID-19) without vital threats, many people develop severe respiratory failure, leading to fatal consequences. A clinical trial from Wuhan, China has demonstrated, that 86% of the patients who required invasive ventilation and 79% among those who needed a non-invasive ventilatory support died in intensive care units (ICU) [1].
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2019) Revision 4 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2019) Revision 4 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Overview of Planned Or Ongoing Studies of Drugs for the Treatment of COVID-19
    Version of 16.06.2020 Overview of planned or ongoing studies of drugs for the treatment of COVID-19 Table of contents Antiviral drugs ............................................................................................................................................................. 4 Remdesivir ......................................................................................................................................................... 4 Lopinavir + Ritonavir (Kaletra) ........................................................................................................................... 7 Favipiravir (Avigan) .......................................................................................................................................... 14 Darunavir + cobicistat or ritonavir ................................................................................................................... 18 Umifenovir (Arbidol) ........................................................................................................................................ 19 Other antiviral drugs ........................................................................................................................................ 20 Antineoplastic and immunomodulating agents ....................................................................................................... 24 Convalescent Plasma ...........................................................................................................................................
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Current Pharma Research ISSN-2230-7842 CODEN-CPRUE6
    Curr. Pharm. Res. 2016, 6(3), 1860-1876 Current Pharma Research ISSN-2230-7842 CODEN-CPRUE6 www.jcpronline.in/ Research Article A novel stability indicating RP-HPLC method development and validation for estimation of Phenylephrine hydrochloride and Bromhexine hydrochloride in their tablet dosage form. Vanita D. Rohit*1, Jinal Tandel1, Payal Chauhan1, Samir Shah2 *1Department of Quality Assurance, Sardar Patel College of Pharmacy, Bakrol, Anand, India, 2Department of Pharmacology, Sardar Patel College of Pharmacy, Bakrol, Anand, India. Received May 21, 2016; received in revised form June 20, 2016; accepted June 20, 2016 *Corresponding author E-mail address: [email protected] ABSTRACT A novel, specific, sensitive, accurate and economical stability indicating RP-HPLC method was developed for the estimation of Phenylephrine hydrochloride and Bromhexine hydrochloride in their tablet dosage form. Separation was achieved on C18 column (250 × 4.6 mm, 5µm) using Optimized Mobile Phase Water: Acetonitrile (60:40 % v/v) (pH adjusted to 4.5 with 1% OPA) and flow rate maintained at 1.0 ml/min was used. Wavelength was monitored at 215 nm. Both the drugs were subjected to acid, base, oxidation, thermal and photolytic degradation conditions. The retention time of PHN and BHX were found to be 3.24 min and 7.11 min respectively. The linearity response was observed in range of 5-25 µg/ml and 4-20 µg/ml of PHN and BHX respectively. Force degradation study revealed that maximum degradation of PHN and BHX was occur in Photolytic degradation. (Standard 19.88%, Sample 18.07% and standard 19.81%, Sample 18.26%) respectively.
    [Show full text]
  • Bisolvon Chesty Forte Oral Contains Bromhexine Hydrochloride 8 Mg
    NEW ZEALAND DATA SHEET 1 BISOLVON CHESTY FORTE Bromhexine hydrochloride tablets Bromhexine hydrochloride Oral Solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet of Bisolvon Chesty Forte contains bromhexine hydrochloride 8 mg. Each 5mL of Bisolvon Chesty Forte Oral contains bromhexine hydrochloride 8 mg. 3 PHARMACEUTICAL FORM Oral tablet Oral solution 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For use as a mucolytic to break down mucus and help clear the chest in conditions accompanied by excessive mucus secretions, such as in the common cold, influenza, infections of the respiratory tract or in other conditions where excess mucus is produced. 4.2 DOSE AND METHOD OF ADMINISTRATION Dose and Method of administration Do not use in children under 6 years of age. Use in children aged 6 to 11 years only on the advice of a doctor, pharmacist or nurse practitioner. bisolchstyfrteliqtab-ccds1-ds3-17aug21 Page 1 Bisolvon Chesty Forte Tablets: Adults and children 12 years and over: One tablet (8 mg) three times a day when necessary. May be increased to two tablets (16 mg) three times a day for the first seven days. Children 6 – 11 years: 1 tablet three times a day when necessary. Bisolvon Chesty Forte Oral Solution: Adults and children 12 years and over: 5 ml (8 mg) three times a day when necessary. May be increased to 10 ml (16 mg) three times a day for the first seven days. Children 6 – 11 years: 5mL (8 mg) three times a day when necessary. The measuring cup provided should be used for dosing. The oral liquid is alcohol-free and sugar-free and therefore suitable for diabetics.
    [Show full text]
  • Antibiotics, Expectorants, and Cough Suppressants
    Antibiotics, Expectorants, and Cough Suppressants Center For Cardiac Fitness Pulmonary Rehab The Miriam Hospital Objectives • Review the mechanism of action (MOA), dosing, benefits, and various options for: – Expectorants – Cough suppressants – Antibiotics for moderate to severe COPD exacerbations • Macrolides • Respiratory fluoroquinolones • Pseudomonas aeruginaosa coverage expectorants • Limited data to suggest improvements to lung function or overall feelings of well-being • MOA: – Wakes up the nerve in the stomach and causes an increase in airway secretions • Ex: Guaifenesin, ipecac, bromhexine, ammonium salts – Emetics • Other MOAs: – Decrease in mucous thickness or an enhancement of the mucociliary escalator – Mucociliary escalator • 2 parts: – Mucous-producing goblet cells – Ciliated epithelium • Bacteria become trapped in the mucous • Cilia, which are constantly beating, push bacteria up and out of the throat Expectorants • Guaifenesin – Dose • Extended release tabs – 600 to 1200 mg every 12 hours • Immediate release tabs/syrup – 200 to 400 mg every 4 to 6 hours • Max = 2400 mg/24 hours – MOA • Increases hydration of mucous and facilitates clearance of mucous from cilia – Side effects • Dizziness, drowsiness, headache, nausea/vomiting, stomach upset, hypouricemia, skin rash • Water – Helps thin and clear mucous Cough Suppressants • Centrally-acting MOA: – Suppress cough via an action on the central cough center • Ex: Dextromethorphan, codeine, long-acting morphine, gabapentin (off-label) • Peripherally-acting MOA: – Depending upon
    [Show full text]